Vidac Pharma Holding PLC: Initiation of Phase 2B* Clinical Trial for Targeted Treatment of Highly Proliferative Actinic Keratosis Lesions

London (pta007/11.12.2025/09:51 UTC+1)

Vidac Pharma Holdings Plc Announces Initiation of Phase 2B* Clinical Trial for Targeted Treatment of Highly Proliferative Actinic Keratosis Lesions

London, UK – 11 December 2025 – Vidac Pharma Holdings Plc., (Dusseldorf, Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) a clinical-stage biopharmaceutical company focused on developing first-in-class treatments for oncology and dermatology is pleased to announce the initiation of its Phase 2B* clinical trial evaluating a novel targeted therapeutic approach for the treatment of highly proliferative lesions of Actinic Keratosis (AK) with its Tuvatexib (VDA1102) ointment. This milestone follows receipt of clearance from the European Medicines Agency (EMA) to proceed with the study.

The trial will investigate Vidac Pharma's innovative treatment designed to eliminate high-risk AK lesions, which have a significantly increased likelihood of progressing to Squamous Cell Carcinoma (SCC), a potentially dangerous and invasive form of skin cancer. The EMA's authorization reflects both the scientific robustness of the protocol and the urgent clinical need for improved treatment options for patients with proliferative AK.

This milestone has been made possible through a strong scientific collaboration between CentroDerm in Wuppertal, Germany—led by Prof. Thomas Dirschka, Head of CentroDerm—the Vidac Pharma research team, and the dedicated support of the Forschungsdock CRO team, whose operational expertise has been instrumental in bringing the study to initiation.

"Such close collaboration was essential in developing this innovative and highly specialized clinical research protocol," said Dr. Max Herzberg, CEO of Vidac Pharma Holdings Plc. "We are proud to work alongside Prof. Thomas Dirschka and CentroDerm, as well as the Forschungsdock CRO team, to advance this important study, which may offer a meaningful new therapeutic option for patients with proliferative Actinic Keratosis. The activation of today includes comprehensive presentations both scientific and clinical to the participating physicians and personnel to ensure enough Q&A time for motivating all involved participants "

The Phase 2B* clinical trial is being activated at the participating clinical site, to ensure precise patient enrollment expected to begin shortly.

For more information please contact:
Vidac Pharma Holding Plc
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase-2 metabolic checkpoint (HK2) in cancer cells to renormalize the tumor microenvironment and selectively provoke programmed cell death without affecting surrounding normal tissue.
VDA-1102, Vidac Pharma's first drug candidate, has demonstrated effectiveness against advanced Actinic Keratosis (AK), while interim Phase 2 results in Cutaneous T-Cell Lymphoma (CTCL) have shown promising clinical benefit in humans.

Important Information

The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding Plc, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "may," "will," "plans," "continue," "ongoing," "potential," "predict," "project," "target," "seek," or "should," and include statements the Company makes concerning the intended results of its strategy.
By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf (Primärmarkt), Hamburg, Stuttgart